Charmacy Pharmaceutical Reshapes Company Secretarial and Governance Roles

An update from Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) is now available.

Charmacy Pharmaceutical announced that the Hong Kong Stock Exchange has confirmed Ms. Yao Jiexi now fully meets the qualification requirements to serve as the company secretary, following an earlier waiver period. As a result, she will assume the role of sole company secretary after the resignation of joint company secretary Ms. Wong Wai Ling, who is leaving without any dispute with the board.

The board also appointed Ms. Lam Wai Yee Sophie, a vice president at SWCS Corporate Services Group (Hong Kong) Ltd., as the company’s alternate authorised representative under the Listing Rules and authorised representative under the Hong Kong Companies Ordinance, effective 27 March 2026. These changes tighten Charmacy’s compliance and governance framework, reinforcing its regulatory interface and corporate secretarial support as it continues to operate in the Hong Kong capital market.

The most recent analyst rating on (HK:2289) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Charmacy Pharmaceutical Co., Ltd. Class H stock, see the HK:2289 Stock Forecast page.

More about Charmacy Pharmaceutical Co., Ltd. Class H

Charmacy Pharmaceutical Co., Ltd. is a Mainland China-based pharmaceutical company listed in Hong Kong, operating in the drug and healthcare sector. The group focuses on the distribution and related services of pharmaceutical products, serving hospitals, medical institutions, and the broader healthcare market in the People’s Republic of China.

Average Trading Volume: 10,700

Technical Sentiment Signal: Sell

Current Market Cap: HK$627.5M

For detailed information about 2289 stock, go to TipRanks’ Stock Analysis page.